Interim Results

Cientifica PLC

("Cientifica" or "the Company")

Unaudited Interim Results

Cientifica (AIM: CTFA.L) (formerly Avia Health Informatics Plc), announces its unaudited interim results for the six months ended 30 September 2013. Comparative figures relate to the six months ended 30 September 2012 (which have been restated) unless otherwise stated. The results refer to a period prior to the restructuring of the Company, disposal of its operating subsidiary, resumption of trading as an investing company in October and its subsequent name change to Cientifica.

Cientifica is an AIM quoted investing company focussing on the acquisition of businesses making use of emerging technologies. The initial target market is applications of graphene technology.

Financials

· Operating loss and loss before tax for the period of £73,892 (H1 2012: £239,234)

· Loss per share for the period was 1.24p (H1 2012 loss: 7.46p)

Corporate

· Proposals put to shareholders for the disposal of Plain Healthcare, a Creditors Voluntary Arrangement (CVA), the adoption of an investing policy and change of name

· Following the period end, the disposal of Plain Healthcare, the CVA, the new Investing Policy and change of name were approved, a new Board was appointed and £380,000 before expenses raised through share placings

Tim Harper, Chief Executive, Cientifica PLC commented:

"These results are not relevant to the on-going business. Following the restructuring in October we believe we now have the platform in place to build a substantial business based on generating revenue and profits from applications of graphene.

"We have a number of acquisition targets, each of which would allow us to enter a different segment of the market, and discussions have commenced".

6th December 2012

Enquiries:

Chairman's Statement

The Company's former healthcare business continued to experience trading difficulties from the start of the current financial year. Sales disappointed and were behind the Directors' expectations due to ordering delays within the NHS, the Company's principal customer, and cash flow continued to be tight.

In late June 2013, after further ordering delays in the NHS, which resulted in a deferral of expected revenues, and a delay in entering into an agreement to licence the Company's technology to a third party, the Company announced that it had requested the suspension of its Ordinary Shares from trading on AIM, pending clarification of its financial position.

All identified options were explored in the latter part of June and in the months up to September 2013. The Board subsequently determined that the orderly disposal of Plain Healthcare Limited would most likely realise some value for shareholders and creditors. On 19 September 2013, the Company announced that it proposed to dispose of Plain Healthcare Limited to Advanced Computer Software Plc, enter into a Creditors Voluntary Arrangement ("CVA"), adopt a new Investing Policy pursuant to Rule 15 of the AIM Rules for Companies and change the name of the Company to "Cientifica plc". On 23 October 2013, these and other related proposals were completed and the Company's enlarged issued share capital resumed trading on AIM.

Financial Report

The consolidated results for the six month period to 30 September 2013 showed revenues of £Nil (*2012: £64,125) and an operating loss and loss before tax of £73,892 (*2012: £239,234)

The loss per share for the period was 1.24p (H1 2012 loss: 7.46p). The cash balance in the Group stood at £2,179 at the end of the period (30 September 2012: £136,967). Save for the £350,000 interest free convertible loan from Advanced Computer Software Group PLC, the Company had no borrowings.

* restated

Current Trading, Going Concern and Outlook

Cientifica is now an AIM quoted investing company with a new management team focussed on the acquisition of businesses making use of advanced materials, in particular graphene, and emerging technologies.

Through the CVA, the Company has settled its creditors, it now has no debt and, following placings in October 2013, has cash resources which will be applied to potential acquisition due diligence and general working capital requirements.

Graphene is currently one of the hottest emerging technologies and is attracting large amounts of interest from scientists, companies and investors alike. Our strategy is not to manufacture graphene - there are plenty of companies doing that and they are all at the bottom end of the value chain - but to develop new applications which apply graphene to address major markets.

With the European Commission funding research to the tune of €1bn over the coming decade, and Cientifica's strong links to the academic community, we are confident that we can identify and develop high value added applications of graphene with commercial potential. This allows us to build a robust technology business rooted in our deep understanding of graphene, but focussing on revenue generating applications.

Unaudited Financial Results for the Six Month Period Ended 30 September 2013

The reader is reminded that these results are unaudited and, as such, may be subject to material change. Both the audited results for the financial year ended 31 March 2013 and the unaudited results for the first half of the current financial year are prepared on the going concern basis, which assumes the Group will have sufficient resources to enable it to continue trading for the foreseeable future.

Unaudited Financial Results for the six month period ended 30 September 2013

\* The comparative figures for the 6 months to 30 September 2012 and year ended 31 March 2013 have been restated to reflect the contribution to the results of operations that have been discontinued in 2013.

Notes to the Interim Report

1. Basis of Preparation and accounting policies

These condensed interim statements have been prepared in accordance with IAS 34, 'Interim Financial Reporting', as adopted by the European Union on a basis consistent with International Financial Reporting Standards (IFRS). They do not contain all of the information required for full financial statements and should be read in conjunction with the consolidated financial statements of the Group as at and for the year ended 31 March 2013. These interim financial statements do not constitute statutory accounts within the meaning of the Companies Act 2006.

The interim financial information was approved by the Board of Directors on 5th December 2013.

The information relating to the six month periods to 30 September 2013 and 30 September 2012 is unaudited. The reader's attention is drawn to the text above under the heading beginning "Unaudited Financial Results for the six month period ended 30 September 2013".

The information relating to the year ended 31 March 2013 is extracted from the audited Financial Statements of the Company which were published on 22 October 2013.

The accounting policies applied by the Group in these interim financial statements are the same as those applied by the Group in its consolidated financial statements for the year ended and as at 31 March 2013.

2. Earnings per share

3. Segmental Information

A segment is a distinguishable component of the Group that is engaged in providing services in a particular economic environment which have different potentials for future development. The Group operates in only one segment and though there is export revenue this is all within Europe and the Company classifies its operations as a single segment.

4. Statement of Compliance

The financial information set out above does not constitute the Company's statutory report and accounts for the year ended 31 March 2013. Statutory Accounts for 2013 have been delivered to the registrar of companies. The auditor's report in respect of the 2013 accounts was unqualified and did not contain a statement under section 489(2) or 498(3) of the Companies Act 2006. It did, however, indicate the existence of a material uncertainty which may cast significant doubt about the Group's ability to continue as a going concern, which the auditor drew attention by way of an emphasis of matter.

5. Directors' Responsibility Statement

The interim report is the responsibility of, and has been, approved by the Directors. The Directors are responsible for preparing the interim financial statements in accordance with the AIM Rules for Companies.

ENDS